These findings underscore the effectiveness of simultaneously targeting two pivotal regulators of the MYC protein family, BRD4 and polo-like kinase-1, using single small molecules, highlighting their potent and selective antitumor capabilities in pediatric cancer models. This evidence concerns the gene MYC and cancer.